Michael Von Forstner | Co-chair, Pharmacovigilance Working Group
Medicines for Europe

Michael Von Forstner, Co-chair, Pharmacovigilance Working Group, Medicines for Europe

Dr. Michael Forstner is Managing Director and Head of the Pharmacovigilance&Pharmacoepidemiology Practice at Mesama Consulting Switzerland, where his main focus areas are the planning, development, implementation and evaluation of (benefit-)risk management solutions, as well as development and application of novel methodologies in signal detection. Amongst his duties are also the coordination of a multi-company, multi-centre PASS, the optimization of processes around benefit-risk management (incl. CAPA management), and until recently ad interim PV department management. Michael is also frequently giving trainings at DIA courses, at the Biocenter Basel (ECPM), at companies and national regulatory authorities.
Before entering into his current role, Dr. Forstner was Head of Regional Pharmacovigilance Europe at Boehringer-Ingelheim, where his main focus had been to establish a proactive and highly integrated benefit-risk management organization with strong links to other functions, while maintaining compliance with all local regulations in the 35 countries of his region. Prior to this, he was Process Development Leader in Drug Safety and Chair of the global Risk Management Working Group at Roche, Basel, where he was responsible for all aspects of global benefit-risk management planning and the implementation of RMPs, including global deployment of additional Risk Minimisation Measures and the evaluation of their effectiveness. Before entering into drug safety, Michael worked in a variety of positions in pharmaceutical R&D at Pharmacia (Nerviano, Italy) and Novartis (Basel, Switzerland), focusing mostly on signal transduction pathways in oncology and CNS disorders, and in drug liability risk management at Zurich Financial Services.
Michael studied biochemistry and medicine in Graz, Austria, holds a PhD in biochemistry from the Swiss Federal Institute of Technology (ETH) Zurich, Switzerland, did postdoctoral work at UC Berkeley/Lawrence Livermore National Laboratory, California in the area of structural enzymology and biophysics, and was Assistant Professor of Molecular Structural Biology at Sveriges Lantbruksuniversitetet in Uppsala, Sweden. Recently he also obtained a postgraduate certificate in Pharmacovigilance and Pharmacoepidemiology from the London School of Hygiene and Tropical Medicine, and was elected a Fellow of the Royal Society for Public Health (FRSPH) in 2016 and a Fellow of the Royal Society of Medicine (FRSM) in 2017.
In his spare time, Michael loves to spend time outdoors with his children and dogs and to engage in various activities from skiing and hiking, to fishing, hunting, horseback riding and gardening. He is also an avid reader, and loves the opera and music in general.


Day One World Drug Safety Congress EU 2018 @ 16:10

Evaluating the effectiveness of risk minimization activities

last published: 14/Aug/18 08:35 GMT

back to speakers